ADAG

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

Adagene reports favorable muzastotug trial results with strong cash position

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Adagene&#039;s latest results demonstrate a 29% response rate for muzastotug in MSS colorectal cancer, suggesting significant therapeutic potential. With a strong cash balance expected to last until early 2028, Adagene is well-positioned for upcoming trials and developments in its pipeline.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Muzastotug shows 29% response in MSS CRC, enhancing treatment landscape.</li><li>Median overall survival for 10 mg/kg cohort is 19.4 months.</li><li>4% overall discontinuation rate indicates improved tolerability of muzastotug.</li><li>Registration trial anticipated post optimization of dose regimen.</li><li>Cash runway extended into early 2028 with $74.5 million cash balance.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Merck (MRK)</strong>: Collaboration with Merck&#039;s KEYTRUDA enhances muzastotug&#039;s profile.</li><li><strong>Sanofi (SNY)</strong>: Sanofi&#039;s investment supports Phase 2 study of muzastotug.</li><li><strong>Roche (RHHBY)</strong>: Roche collaboration evaluates muzastotug in liver cancer trials.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The report falls under Corporate Developments as it discusses clinical trial updates and financial positioning, significant for investor evaluations amid ongoing drug developments.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>29% confirmed response rate for muzastotug may drive investor interest.</li><li>Upcoming trial results in 1H 2027 could impact stock performance significantly.</li><li>Cash runway extending into early 2028 mitigates financial risk.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Muzastotug shows 29% ORR among 21 patients.</li><li>10 mg/kg median overall survival is 19.4 months.</li><li>Cash and cash equivalents total $74.5 million as of December 31, 2025.</li><li>4% overall discontinuation rate across dose cohorts.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Buy ADAG in the near term due to positive trial data and solid cash runway.</p>
  </section>
</section>


<article>
    <h2>Adagene Reports Full Year 2025 Financial Results and Corporate Update</h2>
    <p>SAN DIEGO, Calif. and SUZHOU, China, April 1, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/quote/ADAG">ADAG</a>), a clinical-stage biotechnology company focused on developing innovative antibody-based therapies, has announced its financial results for the full year 2025, alongside critical corporate developments.</p>',
    
    <section>
        <h3>Key Financial Metrics and Operations Overview</h3>
        <p>As of December 31, 2025, Adagene reported cash and cash equivalents of <strong>$74.5 million</strong>. This figure, combined with funds raised from its ATM offering in 2026, provides a cash runway projected to extend into early 2028.</p>
        <ul>
            <li><em>Muzastotug</em> demonstrated a confirmed overall response rate (ORR) of <strong>29%</strong> among 21 patients with microsatellite stable colorectal cancer (MSS CRC) in the 20 mg/kg dosage cohort.</li>
            <li>Median overall survival (OS) for patients in the 10 mg/kg cohort was recorded at <strong>19.4 months</strong>.</li>
            <li>The overall discontinuation rate across all evaluated cohorts stood at just <strong>4%</strong>, indicating a favorable tolerability profile without any reported Grade 4 or 5 treatment-related adverse events (TRAEs).</li>
        </ul>
    </section>

    <section>
        <h3>Clinical Trials and Future Objectives</h3>
        <p>Adagene has seen positive momentum with its ongoing clinical trials. Enrollment for the randomized Phase 2 trial is ahead of schedule, with results expected in the first half of 2027. A registration trial will commence once the optimal dosage regimen has been established.</p>
        <p>Dr. Peter Luo, Chairman and President of R&D at Adagene, stated, “Our clinical data for muzastotug plus pembrolizumab consistently demonstrate potent, dose-dependent efficacy. The 10 mg/kg data reported at ASCO have matured into a classic survival curve, significantly mitigating severe toxicities, thereby allowing patients to remain on therapy longer.”</p> 
        <p>The company's objectives for 2026 include:</p>
        <ul>
            <li>Updating data from the ongoing Phase 1b/2 study of muzastotug in combination with Merck's anti-PD-1 therapy, KEYTRUDA&reg; (pembrolizumab) in advanced MSS CRC.</li>
            <li>Completing enrollment in the randomized Phase 2 dose-optimization study.</li>
            <li>Providing preliminary clinical data for neoadjuvant muzastotug plus pembrolizumab in colorectal cancer.</li>
            <li>Sharing trial results evaluating muzastotug in combination therapies for hepatocellular carcinoma (HCC).</li>
        </ul>
    </section>

    <section>
        <h3>Pipeline Highlights and Research Presentation</h3>
        <p>Adagene's <em>ADG126</em> Phase 1b/2 trials have yielded promising data:</p>
        <ul>
            <li>Confirmed a 29% ORR in the 20 mg/kg cohorts.</li>
            <li>Achieved a median OS of 19.4 months in the 10 mg/kg cohorts, significantly higher than the 11-12 months seen in prior studies.</li>
            <li>Reported minimal toxicity, with a 4% overall discontinuation rate and manageable Grade 3 TRAEs noted at 15% and 27% in the two primary cohorts.</li>
        </ul>
        <p>The American Association for Cancer Research (AACR) 2026 is expected to feature two key abstracts, including evaluations of muzastotug's efficacy in combination with standard treatments.</p>
    </section>
</article>

Adagene's latest results demonstrate a 29% response rate for muzastotug in MSS colorectal cancer, suggesting significant therapeutic potential. With a strong cash balance expected to last until early 2028, Adagene is well-positioned for upcoming trials and developments in its pipeline.

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News